325 related articles for article (PubMed ID: 29659040)
1. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Papageorgiou SG; Vasilatou D; Kontos CK; Kotsianidis I; Symeonidis A; Galanopoulos AG; Hatzimichael E; Megalakaki A; Poulakidas E; Diamantopoulos P; Vassilakopoulos TP; Zikos P; Papadaki H; Mparmparousi D; Bouronikou E; Panayiotidis P; Viniou NA; Pappa V
Am J Hematol; 2018 Jul; 93(7):895-901. PubMed ID: 29659040
[TBL] [Abstract][Full Text] [Related]
2. Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
Cluzeau T; Mounier N; Karsenti JM; Richez V; Legros L; Gastaud L; Garnier G; Re D; Montagne N; Gutnecht J; Gabriel Fuzibet J; Auberger P; Raynaud S; Cassuto JP
Am J Hematol; 2013 Sep; 88(9):780-3. PubMed ID: 23757315
[TBL] [Abstract][Full Text] [Related]
3. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
4. Monosomal karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes.
McQuilten ZK; Sundararajan V; Andrianopoulos N; Curtis DJ; Wood EM; Campbell LJ; Wall M
Cancer; 2015 Sep; 121(17):2892-9. PubMed ID: 26043022
[TBL] [Abstract][Full Text] [Related]
5. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.
Valcárcel D; Ademà V; Solé F; Ortega M; Nomdedeu B; Sanz G; Luño E; Cañizo C; de la Serna J; Ardanaz M; Marco V; Collado R; Grau J; Montoro J; Mallo M; Vallespí T
J Clin Oncol; 2013 Mar; 31(7):916-22. PubMed ID: 23319689
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.
Gangat N; Patnaik MM; Begna K; Kourelis T; Knudson RA; Ketterling RP; Hodnefield JM; Hanson CA; Pardanani A; Tefferi A
Am J Hematol; 2013 Aug; 88(8):690-3. PubMed ID: 23686868
[TBL] [Abstract][Full Text] [Related]
7. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
[TBL] [Abstract][Full Text] [Related]
9. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Papageorgiou SG; Kontos CK; Kotsianidis I; Vasilatou D; Symeonidis A; Galanopoulos A; Bouchla A; Hatzimichael E; Repousis P; Zikos P; Viniou NA; Poulakidas E; Vassilakopoulos TP; Diamantopoulos P; Diamantopoulos MA; Mparmparousi D; Bouronikou E; Papadaki H; Panayiotidis P; Pappa V
Hematol Oncol; 2018 Oct; 36(4):693-700. PubMed ID: 30129144
[TBL] [Abstract][Full Text] [Related]
10. Monosomal karyotype in MDS: explaining the poor prognosis?
Schanz J; Tüchler H; Solé F; Mallo M; Luño E; Cervera J; Grau J; Hildebrandt B; Slovak ML; Ohyashiki K; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Valent P; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Le Beau MM; Bennett JM; Greenberg P; Germing U; Haase D
Leukemia; 2013 Oct; 27(10):1988-95. PubMed ID: 23787396
[TBL] [Abstract][Full Text] [Related]
11. Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.
Ustun C; Trottier BJ; Sachs Z; DeFor TE; Shune L; Courville EL; Holtan SG; Dolan M; Weisdorf DJ; Warlick ED
Biol Blood Marrow Transplant; 2015 May; 21(5):866-72. PubMed ID: 25620751
[TBL] [Abstract][Full Text] [Related]
12. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
Lübbert M; Suciu S; Hagemeijer A; Rüter B; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Schaefer HE; Bogatyreva L; Aul C; de Witte T; Ganser A; Becker H; Huls G; van der Helm L; Vellenga E; Baron F; Marie JP; Wijermans PW;
Ann Hematol; 2016 Jan; 95(2):191-9. PubMed ID: 26596971
[TBL] [Abstract][Full Text] [Related]
13. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype.
Patnaik MM; Hanson CA; Hodnefield JM; Knudson R; Van Dyke DL; Tefferi A
Leukemia; 2011 Feb; 25(2):266-70. PubMed ID: 21072042
[TBL] [Abstract][Full Text] [Related]
14. Monosomal karyotypes apart from complex karyotypes independently predict the outcome of myelodysplastic syndrome patients using a fluorescence in situ hybridization panel and conventional cytogenetics.
Wang N; Xu H; Li Q; Liu J; Sui X; Jiang Y; Fang X; Zhen C; Ding M; Yuan D; Zhang L; Wang X
Int J Lab Hematol; 2019 Aug; 41(4):519-529. PubMed ID: 31066997
[TBL] [Abstract][Full Text] [Related]
15. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.
Vidal V; Robert G; Goursaud L; Durand L; Ginet C; Karsenti JM; Luciano F; Gastaud L; Garnier G; Braun T; Hirsch P; Raffoux E; Nloga AM; Padua RA; Dombret H; Rohrlich P; Ades L; Chomienne C; Auberger P; Fenaux P; Cluzeau T
Oncotarget; 2017 Jul; 8(29):47103-47109. PubMed ID: 28514758
[TBL] [Abstract][Full Text] [Related]
16. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
[TBL] [Abstract][Full Text] [Related]
17. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
[TBL] [Abstract][Full Text] [Related]
18. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia.
van Gelder M; de Wreede LC; Schetelig J; van Biezen A; Volin L; Maertens J; Robin M; Petersen E; de Witte T; Kröger N;
Leukemia; 2013 Apr; 27(4):879-88. PubMed ID: 23164802
[TBL] [Abstract][Full Text] [Related]
19. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
20. Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome.
Xing R; Li C; Gale RP; Zhang Y; Xu Z; Qin T; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Am J Hematol; 2014 Oct; 89(10):E163-8. PubMed ID: 25044281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
